BOCA RATON, Fla., Nov. 16, 2012 /PRNewswire/ -- Sensus Healthcare, providers of the SRT-100, the leading alternative for non surgical skin cancer treatment, announces that it has received a Medical Device License from Health Canada, permitting the marketing and sale of its device for treating skin cancer patients. The SRT-100™ is a state-of-the-art therapy device for Non Melanoma Skin Cancer. The SRT-100™ provides patients with a virtually pain-free non-invasive treatment option, while achieving excellent clinical outcomes that are comparable to surgery, and without scarring. Sensus Healthcare has reintroduced superficial radiotherapy (SRT) and is the leader in the global clinical community. The SRT-100 is proven to be a viable, safe, and cost-effective modality to treat non-melanoma skin cancers in hospitals and private practice settings.
"We are excited to offer this leading technology alternative to the many patients throughout Canada who are diagnosed with skin cancer. We consider Canada as one of the foremost authorities in providing cost effective technologies and we are delighted to have the SRT-100 considered as a viable choice. We are looking forward to working with Canada's healthcare professionals," stated Joe Sardano, President/CEO, Sensus Healthcare.
SRT-100™ is an ideal treatment modality for non-melanoma skin cancers, thanks to its SharpBeam™ characteristics, where only the targeted lesion is being treated, while the surrounding and underlying healthy tissue is spared. The SRT-100™ is FDA, CE, Health Canada, and SFDA cleared and is manufactured in the United States of America under the stringent ISO-13485 and GMP quality standards.
About Sensus Healthcare:
Sensus Healthcare specializes in making proven non-melanoma skin cancer solutions more accessible to patients. Our dedicated superficial radiation therapy (SRT) systems are designed specifically to provide an alternative to surgical procedures for basal cell and squamous cell carcinomas. Our mobile, compact SRT-100™ systems are used widely by oncologists and dermatologists to bring non-melanoma skin cancer treatment to more patients in more settings.
561-922-5808 Ext. 10
|SOURCE Sensus Healthcare|
Copyright©2012 PR Newswire.
All rights reserved